Literature DB >> 20635978

Chemokine-chemokine receptors in cancer immunotherapy.

Trina J Stewart1, Mark J Smyth.   

Abstract

A surge in interest in the chemokine-chemokine receptor network is probably related to the expanding roles that chemokines have now been identified to play in human biology, particularly immunity. Specific tissue microenvironments express distinct chemokines and both hematopoietic and nonhematopoietic cells have receptor expression profiles that permit the coordinated trafficking and organization of cells within these specific tissues. Since the chemokine network plays critical roles in both the function of the immune system and the progression of cancer, it is an attractive target for therapeutic manipulation. This review will focus on chemokine and chemokine receptor network-related therapeutic interventions that utilize host-tumor interactions particularly involving the immune system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20635978     DOI: 10.2217/1750743X.1.1.109

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  12 in total

1.  CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.

Authors:  T Nguyen-Hoai; M Pham-Duc; M Gries; B Dörken; A Pezzutto; J Westermann
Journal:  Cancer Gene Ther       Date:  2016-04-08       Impact factor: 5.987

2.  CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.

Authors:  Qiu Tang; Jun Jiang; Jian Liu
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

3.  CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk: a meta-analysis based on 20,625 subjects.

Authors:  Houqun Ying; Jie Wang; Xueren Gao
Journal:  Tumour Biol       Date:  2014-04-01

Review 4.  Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.

Authors:  Melissa G Lechner; Sarah M Russell; Rikki S Bass; Alan L Epstein
Journal:  Immunotherapy       Date:  2011-11       Impact factor: 4.196

Review 5.  The role of CXC chemokines and their receptors in the progression and treatment of tumors.

Authors:  Qingchao Zhu; Xiaodong Han; Jiayuan Peng; Huanlong Qin; Yu Wang
Journal:  J Mol Histol       Date:  2012-06-30       Impact factor: 2.611

6.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Authors:  Deborah A Knight; Shin Foong Ngiow; Ming Li; Tiffany Parmenter; Stephen Mok; Ashley Cass; Nicole M Haynes; Kathryn Kinross; Hideo Yagita; Richard C Koya; Thomas G Graeber; Antoni Ribas; Grant A McArthur; Mark J Smyth
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

Review 7.  Big opportunities for small molecules in immuno-oncology.

Authors:  Jerry L Adams; James Smothers; Roopa Srinivasan; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2015-07-31       Impact factor: 84.694

Review 8.  Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy.

Authors:  Gregory P Takacs; Joseph A Flores-Toro; Jeffrey K Harrison
Journal:  Pharmacol Ther       Date:  2020-12-11       Impact factor: 12.310

9.  A role for CCL2 in both tumor progression and immunosurveillance.

Authors:  Ming Li; Deborah A Knight; Linda A Snyder; Mark J Smyth; Trina J Stewart
Journal:  Oncoimmunology       Date:  2013-07-01       Impact factor: 8.110

Review 10.  HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.

Authors:  Atefeh Arab; Rezvan Yazdian-Robati; Javad Behravan
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2020-01-09       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.